Folie 1

•

Is SBRT replacing systemic therapy?

•

Or should they be combined?

•

TOAD trial

(Duchesne et al, ASCO 2015): immediate versus delayed ADT

at PSA relapse after definitive therapy

–

HR=0.55 (CI: 0.30-1.00)

•

CHAARTED-

(Sweeney et al NEJM 2015): ADT+docetaxel versus ADT alone

in advanced stage hormone sensitive PCa

–

HR=0.61 (CI: 0.47-0.80)

–

m-OS: 58 and 44 months, respectively

•

STAMPEDE

(James et al Lancet 2016): SOC+docetaxel versus SOC in

advanced stage hormone sensitive PCa

–

HR=0·78 (CI: 0·66–0·93)

•

Combination with immune stimulating agents

SBRT of prostate cancer and systemic therapies